Industry Profile: Alcon

June 2, 2012

As the global leader in eye care, Alcon’s mission is to provide innovative products that enhance quality of life by helping people see better. This mission means that Alcon’s more than 23,000 associates strive to make significant contributions to preserve, restore and enhance vision.

Through the merger of Novartis and Alcon, uniting the strengths of Alcon, CIBA VISION and Novartis Ophthalmics into one eye care business, Alcon has become the second largest division of Novartis. With these collective resources and scale, Alcon now offers the widest spectrum of eye care products in surgical, pharmaceutical and vision care across 180 markets and runs operations in 75 countries.

Alcon has nearly 2,000 people dedicated to research and development around the world working to address the world’s most pressing eye care needs. Alcon products and technologies address growing clinical problems in areas, such as cataracts, glaucoma, retinal diseases, refractive errors, ocular allergies, dry eye, infection and inflammation, and many other eye care needs.

Additionally, Alcon has a strong commitment to its partnership with eye care professionals and humanitarian organizations to embark on medical missions and other activities that address preventable blindness in the world’s most fragile communities.

Research and development

With the largest corporate research and development commitment of any eye care company worldwide, Alcon is currently developing products to treat cataracts, glaucoma, age-related macular degeneration, retinal diseases, dry eye, infection, inflammation, ocular allergies, refractive errors and other ocular health issues. Additionally, the CIBA VISION research and development capability expands Alcon’s product development focus into contact lenses.

In 2010, Alcon spent nearly $750 million on research and development, an increase of more than 12 percent over 2009. Over the next five years, Alcon plans to invest approximately USD 4 billion to drive research and new product development in eye care. With the merger into Novartis, Alcon has gained access to additional research capabilities and resources, including the Novartis Institutes for BioMedical Research, to accelerate product innovation for the eye.

Corporate social responsibility

Alcon is dedicated to reducing the incidence of preventable blindness worldwide. Alcon, together with the Alcon Foundation, donates over $60 million in both cash and in-kind products to charitable activities annually, including patient access assistance programs for low-income patients and more than 1,000 medical missions in more than 100 countries that restore vision to those without access to eye care services.

Alcon also supports ongoing medical training in the latest eye care technologies by supporting more than 200 training locations around the world, most of them based in emerging markets. In addition, Alcon minimizes the impact of our manufacturing operations on the environment with programs such as Product Return & Recycle, Material Declaration, Life Cycle Analysis and Product Stewardship.

For more information, visit www.alcon.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: